TALARIS THERAPEUTICS INC
Talaris Therapeutics, Inc. is a late-clinical stage, cell therapy company developing therapies. The Company is principally focused on developing allogeneic hematopoietic stem cell transplantation (allo-HSCT). The Company's lead product candidate, FCR001, which is central to its facilitated Allo-HSCT therapy, is an allogeneic cell therapy comprised of stem and immune cells that are procured from a healthy donor. FCR001 is processed in the Company's good manufacturing practice (GMP) facility using proprietary manufacturing methods. The Company's clinical programs include FREEDOM-1, FREEDOM-2 and FREEDOM-3. It is advancing a pipeline of programs across three therapeutic categories: solid organ transplantation, severe autoimmune disease, and severe non-malignant blood, immune and metabolic disorders.
Buy US stocks in Australia starting with TALS. Open an account and start investing today!
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in TALS
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.